Conformis Announces New Corporate Headquarters to Accommodate Substantial Growth, Increased Job Creation and Scaled Manufacturing
Existing Burlington space to remain as company’s first standalone manufacturing facility
Bedford, Mass. – November 1, 2012 – Conformis, Inc., a privately held medical device company that is pioneering patient specific orthopedic implants, has relocated its headquarters to 28 Crosby Drive in Bedford, MA. The new space, combined with the manufacturing facility in Burlington, quadruples the total square footage of the company’s existing property. The company now has more than 120,000 square feet available for its operations. The expansion will facilitate the development of advanced manufacturing capabilities, new product development initiatives and a broader commercialization strategy, resulting in more than 100 new jobs over the next 12 to 18 months.
“The expansion to our Bedford facility is an important milestone for Conformis as we continue to grow our application of image-based technology and support the rapid adoption of our personalized knee replacements,” said Philipp Lang, MD, CEO of Conformis. “This brisk growth is a testament to the clinical difference our products make in the lives of patients and the innovation that surgeons feel when they try our technology.”
Conformis recently announced the broad commercial availability of its iTotal® G2 total knee replacement system and the additional manufacturing space will accommodate the growth of this product line as well as its other knee systems. To support its expanded product line, Conformis has also grown its personnel, more than doubling its local employee base in the last two years.
Conformis is retaining its existing facility at 11 North Avenue in Burlington as a manufacturing plant, allowing for scaled production to meet broad commercial demand for its cutting edge knee replacement systems. In 2011, MassDevelopment provided Conformis a $1,445,000 loan from the Emerging Technology Fund to support the company’s manufacturing expansion.
“Thanks to our growth strategy of investing in education, innovation and infrastructure, including our ten-year, $1 billion Life Sciences Initiative, Massachusetts continues to lead the world in life sciences,” said Governor Deval Patrick. “I congratulate Conformis, and appreciate the company’s ongoing commitment to growing in Massachusetts.”
Conformis has won widespread industry recognition for its patient-specific implant systems that are designed to better maintain the patient’s natural anatomy for a more natural feeling knee. In addition, the delivery model helps to reduce costs and streamline the surgical procedures associated with joint replacement surgery. Conformis implants are designed and manufactured individually for each patient based on CT scans of the patient’s joint. In 2010, the company launched the iUni® G2 and iDuo® G2 next-generation systems for partial knee replacement to provide less invasive alternatives to total knee replacement for patients suffering from disease limited to just a portion of the knee. The patient-specific fit of the iTotal G2 implant provides maximum coverage of the joint while retaining the patient’s natural shape with minimal loss of bone.
For more information on Conformis visit www.conformis.com.
About Conformis, Inc.
Conformis, Inc. is a privately-held company that develops and commercializes medical devices for osteoarthritis treatment and joint damage. Its proprietary intellectual property includes more than 350 patents and patent applications in the areas of imaging software, image processing, implant design, surgical techniques, instrumentation, and manufacturing, spanning knee, hip, shoulder, spine, and small joints. Conformis knee implants and instrumentation are designed to address all stages of osteoarthritis, the most common reason for knee replacement surgery. All devices have been cleared by the US Food and Drug Administration for marketing in the US. In 2009, Conformis was named a winner of the Medical Design Excellence Awards for its iUni and iDuo resurfacing implants. In 2011, Conformis received a Medical Design Excellence Award and an American Technology Award for Innovation for the iTotal. Follow Conformis on Twitter at @Conformis and become a fan on Facebook.
90% Patient Satisfaction Reported in Peer-Reviewed Clinical Study of Conformis iTotal PS Knee Replacements
Clinical research published online in July 2020 in The Journal of Bone and Joint Surgery Reviews found that the patients
Conformis Announces 510(k) Clearance for iTotal® Identity PS
iTotal® Identity PS joins iTotal® Identity CR as the latest personalized knee technology from Conformis BILLERICA, Mass., June 22, 2020 (GLOBE NEWSWIRE)